Browsing by Author "Buyukcam, Ayse"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Antifungal Consumption, Indications And Selection Of Antifungal Drugs In Paediatric Tertiary Hospitals in Turkey: Results from The First National Point Prevalence Survey
    (2018) Caglar, Ilknur; Devrim, Ilker; Ozdemir, Halil; Sahbudak, Zumrut; Sonmez, Gulsum; Buyukcam, Ayse; Gulhan, Belgin; Kara, Ahu; Aygun, Deniz F.; Bayram, Nuri; Celebi, Solmaz; Cetin, Benhur; Nepesov, Merve, I; Yilmaz, Ayse T.; Kepenekli, Eda; Ciftdogan, Dilek Yilmaz; Acar, Manolya K.; Yayla, Burcu Cura; Okumus, Canan; Ecevit, Zafer; Hatipoglu, Nevin; Kuyucu, Necdet; Kosker, Muhammed; Sen, Semra; Karbuz, Adem; Sutcu, Murat; Duramaz, Burcu Bursal; Ozen, Metehan; Ciftci, Ergin; Alabaz, Derya; Kurugol, Zafer; Kara, Ates; Kanik, Saliha; Kilic, Omer; Oncel, Selim; Somer, Ayper; Tapisiz, Anil; Belet, Nursen; Akcan, Ozge Metin; Turel, Ozden; Ozkaya, Aslinur; Tezer, Hasan; Cengiz, Ali Bulen; Ince, Erdal; Camcioglu, Yildiz; Kocabas, Emine; Arisoy, Emin S.; Salman, Nuran; 30121343
    Objectives: The aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey. Methods: A point prevalence study was performed at 25 hospitals. In addition to general data on paediatric units of the institutes, the generic name and indication of antifungal drugs, the presence of fungal isolation and susceptibility patterns, and the presence of galactomannan test and high-resolution computed tomography (HRCT) results were reviewed. Results: A total of 3338 hospitalised patients were evaluated. The number of antifungal drugs prescribed was 314 in 301 patients (9.0%). Antifungal drugs were mostly prescribed in paediatric haematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%), paediatric services (18.3%), paediatric ICUs (PICUs) (14.6%) and haematopoietic stem cell transplantation (HSCT) units (7.3%). Antifungals were used for prophylaxis in 147 patients (48.8%) and for treatment in 154 patients (50.0%). The antifungal treatment strategy in 154 patients was empirical in 77 (50.0%), diagnostic-driven in 29 (18.8%) and targeted in 48 (31.2%). At the point of decision-making for diagnostic-driven antifungal therapy in 29 patients, HRCT had not been performed in 1 patient (3.4%) and galactomannan test results were not available in 12 patients (41.4%). Thirteen patients (8.4%) were receiving eight different antifungal combination therapies. Conclusion: The majority of antifungal drugs for treatment and prophylaxis were prescribed in PHO and HSCT units (42.5%), followed by ICUs. Thus, antifungal stewardship programmes should mainly focus on these patients within the availability of diagnostic tests of each hospital. (C) 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Clinical Strains of Chryseobacterium and Elizabethkingia spp. Isolated from Pediatric Patients in a University Hospital: Performance of MALDI-TOF MS-Based Identification, Antimicrobial Susceptibilities, and Baseline Patient Characteristics
    (2017) Mirza, Hasan Cenk; Tuncer, Ozlem; Olmez, Serpil; Sener, Burcin; Tugcu, Gokcen Dilsa; Ozcelik, Ugur; Gursoy, Nafia Canan; Otlu, Baris; Buyukcam, Ayse; Kara, Ates; Sancak, Banu; https://orcid.org/0000-0002-8853-3893; 29227188; F-1232-2015
    Our objective was to evaluate the performance of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) for identification of the Chryseobacterium and Elizabethkingia spp. isolated from pediatric patients at Hacettepe University Hospital using 16S rRNA gene sequencing as the gold standard and to determine the antimicrobial susceptibility patterns of the isolates and baseline characteristics of patients. All stored Chryseobacterium and Elizabethkingia spp. isolated from various clinical specimens (sputum, blood, and urine) of pediatric patients at Hacettepe University Hospital between 2012 and 2016 were included in this study. Minimum inhibitory concentrations of 10 antimicrobial agents were determined by Etest for all isolates. To determine the baseline characteristics of patients, medical records of all patients were retrospectively reviewed. In total, 18 isolates of Chryseobacterium spp. (16 C. indologenes, 2 C. gleum) and 5 isolates of Elizabethkingia spp. (3 E. meningoseptica, 2 E. anophelis) were identified by 16S rRNA sequencing. MALDI-TOF MS correctly identified 19 (82.6%) isolates to the species level. The quinolones (ciprofloxacin and levofloxacin), trimethoprim/sulfamethoxazole and piperacillin/tazobactam showed the highest spectrum of activity against the overall collection of isolates. Cystic fibrosis (CF) was the underlying disease in 81.8% of patients. To our knowledge, this study includes the largest number of Chryseobacterium spp. isolated from clinical specimens of pediatric patients in Turkey. In this study, we also report the first clinical isolate of E. anophelis in Turkey. Since, the majority of strains were isolated from patients with CF; larger, prospective clinical studies are needed to establish whether chryseobacteria could be considered as an emerging opportunistic pathogen in patients with CF.